Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LeMaitre Vascular, Inc. - Common Stock (NQ:LMAT)

97.31 -2.19 (-2.20%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LeMaitre Vascular, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
3 Healthcare Stocks with Open Questions
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloade... 
Via StockStory
Topics Retirement
LeMaitre Vascular Inc (NASDAQ:LMAT): A Quality Investing Candidate Passing All Caviar Cruise Screen Tests ↗
Via Chartmill
News headline image
5 Insightful Analyst Questions From LeMaitre’s Q1 Earnings Call
LeMaitre’s first quarter was marked by double-digit sales growth and significant margin expansion, yet the market responded negatively, reflecting concerns o... 
Via StockStory
Topics Earnings
News headline image
1 High-Flying Stock with Impressive Fundamentals and 2 We Avoid
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta... 
Via StockStory
LeMaitre Vascular (NASDAQ:LMAT) Reports Steady Q1 2026 Results with Earnings Beat and In-Line Revenue ↗
Via Chartmill
Topics Earnings
Minervini Watchlist April 24, 2026 - Before Market Open ↗
Via Chartmill
LeMaitre Vascular Inc (NASDAQ:LMAT) Passes Key Quality Investing Screens ↗
Via Chartmill
News headline image
LMAT Q1 Deep Dive: Artegraft Expansion and Pricing Drive, Margin Upside Meets Cautious Market
Medical device company LeMaitre Vascular (NASDAQ:LMAT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 11.2% year on year to $66.55 millio... 
Via StockStory
News headline image
LeMaitre (NASDAQ:LMAT) Posts Q1 CY2026 Sales In Line With Estimates
Medical device company LeMaitre Vascular (NASDAQ:LMAT) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 11.2% year on year to $66.55 millio... 
Via StockStory
News headline image
LeMaitre (LMAT) Q1 Earnings Report Preview: What To Look For
Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be reporting results this Tuesday after market hours. Here’s what you need to know. LeMaitre beat... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Hyped Up Stocks Walking a Fine Line
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements... 
Via StockStory
News headline image
3 Cash-Heavy Stocks Walking a Fine Line
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o... 
Via StockStory
News headline image
Surgical Equipment & Consumables - Specialty Stocks Q4 Earnings: LeMaitre (NASDAQ:LMAT) Firing on All Cylinders
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - spe... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
3 Russell 2000 Stocks We Steer Clear Of
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory
News headline image
A LeMaitre Vascular (LMAT) Insider Sold 2,625 Shares for $285K ↗
This medical device innovator, focused on vascular surgery solutions, reported a notable insider sale amid steady financial performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
LeMaitre Vascular Up 30% as Insider Sells $285K in Stock. Here's What Investors Should Know ↗
LeMaitre Vascular, a specialist in vascular medical devices, reported a notable insider sale amid strong recent share gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Artivion, Intuitive Surgical, GE HealthCare, LeMaitre, and Globus Medical Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in... 
Via StockStory
Topics Government Stocks
News headline image
3 Unpopular Stocks We’re Skeptical Of
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord... 
Via StockStory
News headline image
3 Cash-Producing Stocks with Warning Signs
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
3 Healthcare Stocks We’re Skeptical Of
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
News headline image
2 Profitable Stocks with Exciting Potential and 1 We Turn Down
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
PacBio, Myriad Genetics, LeMaitre, Hims & Hers Health, and GoodRx Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. The Producer Price Index (PPI), a key... 
Via StockStory
Topics Economy Government Stocks
News headline image
LeMaitre (LMAT) Stock Trades Up, Here Is Why
Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) jumped 16.8% in the morning session after the company reported strong fourth-quarter 2025 results that surpassed Wall Street's... 
Via StockStory
News headline image
LeMaitre (NASDAQ:LMAT) Surprises With Q4 CY2025 Sales, Stock Soars
Medical device company LeMaitre Vascular (NASDAQ:LMAT) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 15.7% year on year to $64.45 million. Guidance for next quarter’s revenue was... 
Via StockStory
News headline image
LeMaitre (LMAT) To Report Earnings Tomorrow: Here Is What To Expect
Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be announcing earnings results this Wednesday after market hours. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 of Wall Street’s Favorite Stock on Our Buy List and 2 We Find Risky
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
News headline image
3 Small-Cap Stocks We Keep Off Our Radar
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
News headline image
1 High-Flying Stock for Long-Term Investors and 2 That Underwhelm
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices,... 
Via StockStory
News headline image
1 Cash-Producing Stock with Solid Fundamentals and 2 We Ignore
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
3 Profitable Stocks That Concern Us
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.